title: Dirlotapide: a review of its properties and role in the management of obesity in dogs.
abstract: Dirlotapide is a microsomal triglyceride transfer protein (MTP) inhibitor developed specifically for canine weight reduction. MTP catalyzes the assembly of triglyceride-rich apolipoprotein-B containing lipoproteins to form chylomicrons in the intestinal mucosa and very low-density lipoproteins in the liver. Following oral administration, dirlotapide has in vivo selectivity for intestinal MTP compared with hepatic MTP. In addition to reducing intestinal fat absorption, dirlotapide also reduces food intake in a dose-dependent manner, probably via increased release of peptide YY into the circulation. The decrease in food intake is responsible for the majority of the weight reduction effect. In clinical use, it is recommended to adjust the dose according to the observed weight loss of each individual. The initial dose of 0.05 mg/kg is doubled after 14 days and then adjusted monthly, the maximum permitted daily dose is 1.0 mg/kg, although doses as high as 10 mg/kg have been administered to dogs without severe adverse experience in safety studies. Dirlotapide can be used without necessitating changes to the current feeding or exercise regimens, but it is desirable to monitor the food intake during weight-stabilization to establish revised feeding and exercise routines that will minimize the risk of weight regain post-treatment. The drug offers a novel approach that is applicable in cases where dietary management alone has proved to be unsuccessful.
authors.affiliation: Pfizer Inc, Veterinary Medicine Research and Development, Kalamazoo, MI 49001, USA. jody.wren@pfizer.com
authors.forename: J A
authors.initials: JA
authors.lastname: Wren
authors.forename: J
authors.initials: J
authors.lastname: Gossellin
authors.forename: S J
authors.initials: SJ
authors.lastname: Sunderland
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002219:Carbamates / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy / Q000662:veterinary*
chemical_list: D019440:Anti-Obesity Agents; D002219:Carbamates; D007211:Indoles; C521290:dirlotapide